Gene therapy for tuberous sclerosis
US-2024343768-A1 · Oct 17, 2024 · US
Compositions and methods for modulation of immune response
US2016354437A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016354437-A1 |
| Application number | US-201515117629-A |
| Country | US |
| Kind code | A1 |
| Filing date | Feb 13, 2015 |
| Priority date | Feb 13, 2014 |
| Publication date | Dec 8, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compositions and methods for modulation of immune response via PYRIN domain-only proteins POP1 and/or POP3. In particular, POP1 and/or POP3 are inhibited to enhance an immune response (e.g., to treat or prevent infection), or POP1 and/or POP3 are administered or activated to reduce an immune response (e.g., to treat or prevent autoimmune or inflammatory disease).
First claim
Opening claim text (preview).
1 . A method of treating or preventing a disease or condition associated with inflammation comprising administering a composition that increases the activity of POP1, POP2, and/or POP3. 2 . The method of claim 1 , wherein the composition comprises a POP1, POP2, and/or POP3 polypeptide, peptide, or peptidomimitic. 3 . The method of claim 2 , wherein the polypeptide or peptide comprises 100% sequence identity with all or a portion of POP1, POP2, or POP3. 4 . The method of claim 2 , wherein the polypeptide or peptide comprises less than 100% sequence identity, but greater than 70% sequence identity with all or a portion of POP1, POP2, or POP3. 5 . The method of claim 1 , wherein the composition comprises an agent that enhances the inflammasome inhibitory activity of POP1, POP2, and/or POP3. 6 . The method of claim 5 , wherein the composition is a small molecule, peptide, polypeptide, protein, or antibody. 7 . The method of claim 1 , wherein the disease or condition is an autoimmune disease. 8 . The method of claim 1 , wherein the disease or condition is an inflammatory disease. 9 . The method of claim 1 , wherein the composition is co-administered with one or more additional treatments for the disease or condition 10 . A method of treating or preventing infection comprising administering a composition that inhibits the activity of POP1, POP2, and/or POP3. 11 . The method of claim 10 , wherein the composition is a small molecule, peptide, polypeptide, protein, or antibody. 12 . The POP1, POP2, or POP3 protein, polypeptide, or peptide that comprises less than 100% sequence identity, but greater than 70% sequence identity with all or a portion of POP1, POP2, or POP3. 13 . A POP1, POP2, or POP3 protein, polypeptide, or peptide for use as a medicament. 14 . The POP1, POP2, or POP3 protein, polypeptide, or peptide of claim 13 , comprising less than 100% sequence identity, but greater than 70% sequence identity with all or a portion of POP1 or POP3. 15 . The POP1, POP2, or POP3 protein, polypeptide, or peptide of claim 13 for use in the treatment or prevention of an autoimmune or inflammatory disease or condition. 16 . A POP1, POP2, or POP3 protein, polypeptide, or peptide for use in the treatment or prevention of an autoimmune or inflammatory disease or condition. 17 . A POP1, POP2, or POP3 inhibitor. 13 . A POP1, POP2, or POP3 protein, polypeptide, or peptide for use as a medicament. 14 . The POP1, POP2, or POP3 protein, polypeptide, or peptide of claim 13 , comprising less than 100% sequence identity, but greater than 70% sequence identity with all or a portion of POP1, POP2, or POP3. 15 . The POP1, POP2, or POP3 protein, polypeptide, or peptide of claim 13 for use in the treatment or prevention of an autoimmune or inflammatory disease or condition. 16 . A POP1, POP2, or POP3 protein, polypeptide, or peptide for use in the treatment or prevention of an autoimmune or inflammatory disease or condition.
Assignees
Inventors
Classifications
- A61K38/1709Primary
from mammals · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016354437A1 cover?
- Provided herein are compositions and methods for modulation of immune response via PYRIN domain-only proteins POP1 and/or POP3. In particular, POP1 and/or POP3 are inhibited to enhance an immune response (e.g., to treat or prevent infection), or POP1 and/or POP3 are administered or activated to reduce an immune response (e.g., to treat or prevent autoimmune or inflammatory disease).
- Who is the assignee on this patent?
- Univ Northwestern
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Dec 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).